Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Change in Receivables (2017 - 2025)

Assembly Biosciences has reported Change in Receivables over the past 9 years, most recently at $62000.0 for Q4 2025.

  • Quarterly results put Change in Receivables at $62000.0 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $974000.0 (up 2365.12% YoY), and the annual figure for FY2025 was $974000.0, up 2365.12%.
  • Change in Receivables for Q4 2025 was $62000.0 at Assembly Biosciences, down from $912000.0 in the prior quarter.
  • Over the last five years, Change in Receivables for ASMB hit a ceiling of $912000.0 in Q3 2025 and a floor of -$1.0 million in Q1 2021.
  • Median Change in Receivables over the past 5 years was -$1000.0 (2022), compared with a mean of -$17066.7.
  • Biggest five-year swings in Change in Receivables: surged 118.31% in 2022 and later tumbled 37400.0% in 2023.
  • Assembly Biosciences' Change in Receivables stood at -$433000.0 in 2021, then soared by 30.25% to -$302000.0 in 2022, then surged by 114.24% to $43000.0 in 2023, then tumbled by 200.0% to -$43000.0 in 2024, then soared by 244.19% to $62000.0 in 2025.
  • The last three reported values for Change in Receivables were $62000.0 (Q4 2025), $912000.0 (Q3 2025), and -$43000.0 (Q2 2024) per Business Quant data.